Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Cash & Equivalents (2016 - 2026)

Angiodynamics' Cash & Equivalents history spans 17 years, with the latest figure at $37.8 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 15.53% year-over-year to $37.8 million; the TTM value through Feb 2026 reached $37.8 million, down 15.53%, while the annual FY2025 figure was $55.9 million, 26.51% down from the prior year.
  • Cash & Equivalents reached $37.8 million in Q1 2026 per ANGO's latest filing, down from $41.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $78.5 million in Q1 2024 to a low of $23.9 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $46.0 million, with a median of $44.6 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: crashed 56.14% in 2022, then skyrocketed 160.54% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $29.9 million in 2022, then surged by 103.96% to $60.9 million in 2023, then decreased by 11.18% to $54.1 million in 2024, then dropped by 23.02% to $41.6 million in 2025, then fell by 9.19% to $37.8 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Cash & Equivalents are $37.8 million (Q1 2026), $41.6 million (Q4 2025), and $38.8 million (Q3 2025).